Sickle Cell Disease with Vaso-Occlusive Crisis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Sickle Cell Disease with Vaso Occlusive Crisis Pipeline Drugs Market Report Overview
Vaso-occlusive crisis associated with sickle cell disease is a painful episode that occurs in people who have sickle cell anemia. Symptoms include fever, pain, fatigue, abdominal pain and swelling, headaches, shortness of breath, dehydration, and infection. Treatment includes NSAIDs, acetaminophen, blood transfusion, and surgery.
The Sickle Cell Disease with Vaso-Occlusive Crisis pipeline drugs market research report provides comprehensive information on the therapeutics under development for Sickle Cell Disease with Vaso-Occlusive Crisis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report offers an overview of key players involved in therapeutic development for Sickle Cell Disease with Vaso-Occlusive Crisis and features dormant and discontinued projects.
Sickle Cell Disease with Vaso-Occlusive Crisis Pipeline Drugs Market Segmentation by Targets
Some of the targets of the Sickle Cell Disease with Vaso-Occlusive Crisis pipeline drugs market are P Selectin, Soluble Guanylate Cyclase, Apolipoprotein A I, Complement C5, DNA Directed RNA Polymerase, E Selectin, L-Citrulline, Prostaglandin G/H Synthase 1, and Prostaglandin G/H Synthase 2.
Sickle Cell Disease with Vaso-Occlusive Crisis Pipeline Drugs Market Analysis, by Targets
For more Sickle Cell Disease with Vaso-Occlusive Crisis pipeline drugs market target insights, download a free report sample
Sickle Cell Disease with Vaso-Occlusive Crisis Pipeline Drugs Market Segmentation by Mechanism of Actions
Some of the mechanisms of action of the Sickle Cell Disease with Vaso-Occlusive Crisis pipeline drugs market are P Selectin Inhibitor, Soluble Guanylate Cyclase Activator, Apolipoprotein A I Activator, Complement C5 Inhibitor, E Selectin Inhibitor, L-Citrulline Replacement, Prostaglandin G/H Synthase 1 Inhibitor, and Prostaglandin G/H Synthase 2 Inhibitor.
Sickle Cell Disease with Vaso-Occlusive Crisis Pipeline Drugs Market Analysis, by Mechanism of Actions
For more mechanism of action insights into the Sickle Cell Disease with Vaso-Occlusive Crisis pipeline drugs market, download a free report sample
Sickle Cell Disease with Vaso-Occlusive Crisis Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the Sickle Cell Disease with Vaso-Occlusive Crisis pipeline drugs market are intravenous, oral, and subcutaneous.
Sickle Cell Disease with Vaso-Occlusive Crisis Pipeline Drugs Market Analysis, by Routes of Administration
For more routes of administration insights into the Sickle Cell Disease with Vaso-Occlusive Crisis pipeline drugs market, download a free report sample
Sickle Cell Disease with Vaso-Occlusive Crisis Pipeline Drugs Market Segmentation by Molecule Types
The molecule types in the Sickle Cell Disease with Vaso-Occlusive Crisis pipeline drugs market are Small Molecule, Monoclonal Antibody, Peptide, and Recombinant Protein.
Sickle Cell Disease with Vaso-Occlusive Crisis Pipeline Drugs Market Analysis, by Molecule Types
For more molecule type insights into the Sickle Cell Disease with Vaso-Occlusive Crisis pipeline drugs market, download a free report sample
Competitive Landscape
Some of the key companies in the Sickle Cell Disease with Vaso-Occlusive Crisis pipeline drugs market are Novartis AG, Alfasigma SpA, Asklepion Pharmaceuticals LLC, Chugai Pharmaceutical Co Ltd, Cyclerion Therapeutics Inc, Global Blood Therapeutics Inc, GlycoMimetics Inc, Hartis Pharma SA, NicOx SA, NuvOx Pharma LLC, and Prolong Pharmaceuticals LLC.
Sickle Cell Disease with Vaso-Occlusive Crisis Pipeline Drugs Market Analysis, by Companies
To know more about the Sickle Cell Disease with Vaso-Occlusive Crisis pipeline drugs market companies, download a free report sample
Sickle Cell Disease with Vaso-Occlusive Crisis Pipeline Drugs Market Report Overview
Key Targets | P Selectin, Soluble Guanylate Cyclase, Apolipoprotein A I, Complement C5, DNA Directed RNA Polymerase, E Selectin, L-Citrulline, Prostaglandin G/H Synthase 1, and Prostaglandin G/H Synthase 2 |
Key Mechanism of Actions | P Selectin Inhibitor, Soluble Guanylate Cyclase Activator, Apolipoprotein A I Activator, Complement C5 Inhibitor, E Selectin Inhibitor, L-Citrulline Replacement, Prostaglandin G/H Synthase 1 Inhibitor, and Prostaglandin G/H Synthase 2 Inhibitor |
Key Routes of Administration | Intravenous, Oral, and Subcutaneous |
Key Molecule Types | Small Molecule, Monoclonal Antibody, Peptide, and Recombinant Protein |
Key Companies | Novartis AG, Alfasigma SpA, Asklepion Pharmaceuticals LLC, Chugai Pharmaceutical Co Ltd, Cyclerion Therapeutics Inc, Global Blood Therapeutics Inc, GlycoMimetics Inc, Hartis Pharma SA, NicOx SA, NuvOx Pharma LLC, and Prolong Pharmaceuticals LLC |
Scope
This report provides:
- A snapshot of the global therapeutic landscape of Sickle Cell Disease with Vaso-Occlusive Crisis.
- Reviews of pipeline therapeutics for Sickle Cell Disease with Vaso-Occlusive Crisis by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which comprise product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- Reviews key companies involved in Sickle Cell Disease with Vaso-Occlusive Crisis therapeutics and enlists all their major and minor projects.
- Evaluation of Sickle Cell Disease with Vaso-Occlusive Crisis therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- All the dormant and discontinued pipeline projects.
- Reviews of the latest news related to pipeline therapeutics for Sickle Cell Disease with Vaso-Occlusive Crisis.
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Sickle Cell Disease with Vaso-Occlusive Crisis.
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Sickle Cell Disease with Vaso-Occlusive Crisis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Asklepion Pharmaceuticals LLC
Chugai Pharmaceutical Co Ltd
Cyclerion Therapeutics Inc
Global Blood Therapeutics Inc
GlycoMimetics Inc
Hartis Pharma SA
NicOx SA
Novartis AG
NuvOx Pharma LLC
Prolong Pharmaceuticals LLC
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets of the Sickle Cell Disease with Vaso-Occlusive Crisis pipeline drugs market?
Some of the key targets of the Sickle Cell Disease with Vaso-Occlusive Crisis pipeline drugs market are the P Selectin, Soluble Guanylate Cyclase, Apolipoprotein A I, Complement C5, DNA Directed RNA Polymerase, E Selectin, L-Citrulline, Prostaglandin G/H Synthase 1, and Prostaglandin G/H Synthase 2.
-
What are the key mechanisms of action in the Sickle Cell Disease with Vaso-Occlusive Crisis pipeline drugs market?
Some of the key mechanisms of action in the Sickle Cell Disease with Vaso-Occlusive Crisis pipeline drugs market are P Selectin Inhibitor, Soluble Guanylate Cyclase Activator, Apolipoprotein A I Activator, Complement C5 Inhibitor, E Selectin Inhibitor, L-Citrulline Replacement, Prostaglandin G/H Synthase 1 Inhibitor, and Prostaglandin G/H Synthase 2 Inhibitor.
-
What are the key routes of administration in the Sickle Cell Disease with Vaso-Occlusive Crisis pipeline drugs market?
The key routes of administration in the Sickle Cell Disease with Vaso-Occlusive Crisis pipeline drugs market are intravenous, oral, and subcutaneous.
-
What are the key molecule types in the Sickle Cell Disease with Vaso-Occlusive Crisis pipeline drugs market?
The molecule types in the Sickle Cell Disease with Vaso-Occlusive Crisis pipeline drugs market are Small Molecule, Monoclonal Antibody, Peptide, and Recombinant Protein.
-
Which are the key companies in the Sickle Cell Disease with Vaso-Occlusive Crisis pipeline drugs market?
Some of the key companies in the Sickle Cell Disease with Vaso-Occlusive Crisis pipeline drugs market are Novartis AG, Alfasigma SpA, Asklepion Pharmaceuticals LLC, Chugai Pharmaceutical Co Ltd, Cyclerion Therapeutics Inc, Global Blood Therapeutics Inc, GlycoMimetics Inc, Hartis Pharma SA, NicOx SA, NuvOx Pharma LLC, and Prolong Pharmaceuticals LLC.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.